You are being asked to participate in this research study because you have been diagnosed with breast cancer and considered for immunotherapy. This study will investigate your response to immunotherapy.

If you are being considered for an EXIT procedure, you may be eligible to participate in our research study.

Do you have triple-negative breast cancer that either came back or did not improve after initial cancer treatment? If so, you may be able to take part in this gene therapy research study to learn more about using your own modified immune cells as a possible treatment.

In this study, we want to learn more about how people understand sentences on a computer screen. We are looking for English speakers who only speak one language and have no trouble reading or speaking. We will see if there are any differences in how people understand them.

Have you recently had an anterior cruciate ligament injury and will be undergoing anterior cruciate ligament reconstruction surgery? If so, you may be able to participate in a study comparing the effects on pain relief and arthritis prevention of metformin or placebo. Compensation provided.

Do you have Alpha-1 Antitrypsin Deficiency? Do you want to participate in research? You may be able to participate in a research project to be contacted for future research studies. Compensation provided.

The purpose of this study is to see if batoclimab is safe and helps people with chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune disorder. Batoclimab is also known as IMVT-1401. Batoclimab is injected under the skin (subcutaneously) and targets the immune system.

Are you interested in improving your physical health and wellbeing during or after cancer treatment? If so, our free 12- week exercise program might be a good fit for you! We are creating a registry of adults with a cancer diagnosis who have gone through our program.

Do you have Stage II or III Breast cancer? If you have enough tissue from your breast cancer diagnosis to send for Mammaprint genomic testing, you may be able to take part in this research study. In this study, we want to learn more about adding an immunotherapy drug, durvalumab, to your chemotherapy treatment. The Mammaprint testing is conducted at no cost to you and the cost of durvalumab is covered.

Can we extend your life after the diagnosis of your cancer in the stomach, esophagus, or gastroesophageal junction by adding a third chemotherapy drug to the usual combination of two chemotherapy drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for treatment of your cancer in the stomach, esophagus, or gastroesophageal junction. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction.